Comment on the editorial by Turner et al. on assessment of cardiovascular risk of new drugs for the treatment of diabetes mellitus: risk assessment vs. risk aversion by Zannad et al

Eur Heart J Cardiovasc Pharmacother. 2017 Jul 1;3(3):129. doi: 10.1093/ehjcvp/pvx006.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Cardiovascular Diseases*
  • Cardiovascular System
  • Humans
  • Risk Assessment*
  • Risk Factors